Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas by unknown
BioMed CentralMolecular Cancer
ssOpen AcceReview
Clinicopathological significance of stromal variables: angiogenesis, 
lymphangiogenesis, inflammatory infiltration, MMP and PINCH in 
colorectal carcinomas
Xiao-Feng Sun*1 and Hong Zhang2
Address: 1Department of Oncology, Institute of Biomedicine and Surgery, University of Linköping, SE-581 85 Linköping, Sweden and 
2Department of Dermatology, Institute of Biomedicine and Surgery, University of Linköping, SE-581 85 Linköping, Sweden
Email: Xiao-Feng Sun* - xiao-feng.sun@ibk.liu.se; Hong Zhang - hong.zhang@ibk.liu.se
* Corresponding author    
Abstract
Cancer research has mainly focused on alterations of genes and proteins in cancer cells themselves
that result in either gain-of-function in oncogenes or loss-of-function in tumour-suppressor genes.
However, stromal variables within or around tumours, including blood and lymph vessels, stromal
cells and various proteins, have also important impacts on tumour development and progression.
It has been shown that disruption of stromal-epithelial interactions influences cellular proliferation,
differentiation, death, motility, genomic integrity, angiogenesis, and other phenotypes in various
tissues. Moreover, stromal variables are also critical to therapy in cancer patients. In this review,
we mainly focus on the clinicopathological significance of stromal variables including angiogenesis,
lymphangiogenesis, inflammatory infiltration, matrix metalloproteinase (MMP), and the particularly
interesting new cysteine-histidine rich protein (PINCH) in colorectal cancer (CRC).
Background
The majority of cancer researchers have been focusing on
tumour cells themselves and investigating their altera-
tions in morphology, biology and function in tumour
processes. However, stromal variables within or around
tumours, including blood and lymph vessels, stromal
cells, and various types of proteins, have not drawn
enough attention even though they have important
impacts on tumour development and progression.
Tumour angiogenesis and lymphangiogenesis are the
processes of creating new blood vessels or lymph vessels
within and surrounding tumours. Stromal cells consist of
various cell types such as infiltrating immune cells, fibrob-
lasts, and endothelial cells. The extracellular matrix
(ECM) is a complex structural entity surrounding tumour
cells, and is often referred to as the connective tissue or
ground substance. The ECM is composed of three major
classes of biomolecules; structural proteins (collagen and
elastin), specialized proteins (fibrillin, fibronectin, and
laminin), and proteoglycans [1,2].
A better understanding of the role of stromal variables in
tumour development is required for designing appropri-
ate therapeutic strategies against angiogenesis and stromal
proteinases. A number of anti-angiogenesis elements and
matrix metalloproteinase (MMP) inhibitors (MMPI) have
recently been developed, and some have reached clinical
trials [3-7]. Compared to tumour cells, stromal variables
are more attractive therapeutic targets, due to lower drug
resistance and few side effects [8].
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Molecular Cancer 2006, 5:43 http://www.molecular-cancer.com/content/5/1/43In this article, we mainly review the clinicopathological
significance of stromal variables, including angiogenesis,
lymphangiogenesis, inflammatory infiltration, MMPs and
the particularly interesting new cysteine-histidine rich
protein (PINCH) in colorectal cancer (CRC).
Angiogenesis and lymphangiogenesis in CRCs
In general, normal tissues have a barrier, preventing either
endothelial cell migration or tumour cell invasion. The
effect of this barrier can be interrupted by newly-formed
stroma, namely stromatogenesis, during the process of
tumour development [9]. Stromatogenesis is probably a
response to messages delivered by tumour cells. The
newly-formed stroma is usually loose and oedematous
and therefore allows endothelial and tumour cells to eas-
ily penetrate it [10].
When a tumour grows larger than 1–2 mm3, it must stim-
ulate the host to creat its own vasculature to be able to
continue growing. To accomplish this process, tumour
cells induce adjacent blood vessels to sprout new vessels
toward the tumour in a process called tumour angiogen-
esis [11]. Since immature microvessels are not covered by
pericyte, and they are irregular and leaky tumour cells can
more easily penetrate immature microvessels than mature
microvessels [12]. Lymphangiogenesis is the process of
creating new lymph vessels within or surrounding a
tumour. As compared with blood capillaries, lymphatic
endothelial cells have even poorly developed junctions
with frequently large inter-endothelial gaps. In addition,
lymphatic vessels have discontinuous or completely
absent basement membranes [13-15]. Lymphangiogen-
esis is a relatively new area of basic and clinical investiga-
tion, and has not been well studied due to a lack of
specific lymphatic vessel markers. The recent discovery of
specific lymphatic vessel markers, and their correspond-
ing antibodies have aided in the identification of lym-
phatic vessels. Importantly, increased interest in this field
has been generated by the discovery of new vascular
endothelial growth factor (VEGF) family members which
play a critical role in lymphangiogenesis [14].
Growth factors in angiogenesis and lymphangiogenesis
Both physiological and pathological stimuli such as
hypoxia induce tumour cells, together with leukocytes,
macrophages, mast cells and platelets, to secrete VEGF
and other growth-related factors such as platelet-derived
growth factor (PDGF) family proteins and their receptors
(PDGFR), insulin-like growth factor (IGF) proteins and
their receptors (IGFR), circulating endothelial precursor
cell (CEPC), fibroblast growth factors (FGF)-2, angiopoi-
etins, EphrinB2 and EphB4 [13]. These factors are then
directly or indirectly involved in angiogenesis and lym-
phangiogenesis, causing endothelial cells of nearby blood
and lymph vessels to divide, migrate and form new vessels
growing toward the tumour. Among these factors, the
VEGF family is the best characterised.
The ligands of the VEGF family include VEGF-A, VEGF-B,
VEGF-C, VEGF-D and VEGF-E. All five ligands have differ-
ent roles in the process of angiogenesis and lymphangio-
genesis. Each of the VEGF-family ligands binds to one or
more of three known VEGF receptors (VEGFR): VEGFR-1
(also known as flt-1), VEGFR-2 (Flk-1 or KDR) and
VEGFR-3 (Flt-4). VEGFR-1 organises blood vessels, and
has a high affinity for VEGF-A and VEGF-B. VEGFR-2 acti-
vates blood vessel proliferation by binding to VEGF-A,
VEGF-C, VEGF-D, and VEGF-E. VEGFR-2 is expressed in
lymphatic endothelial cells [13,16-18]. VEGFR-3 is
expressed on the vascular endothelium, but is mainly
restricted to the lymphatic endothelium. VEGFR-3 binds
to VEGF-C and VEGF-D, and is critical to the growth
migration and survival of lymphatic endothelial cells,
resulting in lymphangiogenesis [19-24].
Angiogenesis in relation to clinicopathological variables
It has been found that high microvessel density (MVD) is
associated with VEGF [25-27] and VEGF-C expression at
the deepest invasive tumour site [24,28]. However, high
MVD is not associated with VEGF-D expression [24]. Sev-
eral studies have demonstrated that MVD gradually
increases from normal mucosa to adenoma and finally to
carcinoma in the colorectum [29-33]. Increased MVD is
detected at the early stages of focal dysplasia, and then
increases gradually from low to high grades of dysplasia
[33]. The transitional mucosa adjacent to the carcinoma
displays intermediate levels of MVD between normal
mucosa and the carcinoma [29]. In the carcinoma, MVD
increases as the tumour invades from the mucosa to the
muscularis propria [32]. The highest level of MVD is
found at the invasive margin of carcinomas [34], a site of
active tumour invasion. These findings indicate that MVD
is an early and critical step in colorectal tumourigenesis
and tumour development.
Many research groups have studied CRC and shown that
a high grade of MVD is related to a larger tumour size
[12,35,36], non-mucinous carcinoma [27], poorer differ-
entiation [12,34], deeper invasion of tumours [12],
advanced Dukes' stage [12,34], lymphatic vessel invasion
[34-36], lymph node metastasis [31,34,36], venous vessel
invasion [34-37], liver metastasis [34], and a higher rate of
recurrence [36,38-40]. Tumours with high levels of MVD
have been connected to poor survival in patients with ear-
lier or advanced colon/rectal cancers [12,27,40-42]. Even
in multivariate analyses, MVD is related to survival in the
whole group of patients with CRC [34,36,38,43] or sub-
groups of patients with stage II-III [44] or stage A-C
tumours [37]. Recently, Yonenaga et al. have analysed a
microvessel pericyte coverage index (an index of micro-Page 2 of 20
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nificance in CRC [12]. The results indicate that immature
neovascularization is observed in poorly differentiated
tumours and further correlated with metastasis, resulting
in a poorer prognosis. Thus, not only microvessel density
but also vessel maturation are crucial factors for the
tumour development and aggressiveness of CRC. Nota-
bly, Yonenaga et al. have applied the anti-α-smooth mus-
cle actin (SMA) marker to determine the microvessel
pericyte coverage index [12]. There are several other com-
mon markers used for pericytes including desmin,
PDGFR-β, VEGFR-1, and neuron-glial antigen 2. It seems
that α-SMA and desmin expression are esentially identical
in pericytes [12,45]. While PDGFR-β, VEGFR-1, and neu-
ron-glial antigen 2 can be positively expressed in pericytes
that are negative for α-SMA, indicating that a lack of α-
SMA expression does not necessarily mean an absence of
pericytes. In other words, PDGFR-β, VEGFR-1, and neu-
ron-glial antigen 2 may be more reliable markers for
determining the presence of pericytes, while α-SMA is
probably only expressed in more stable and mature peri-
cytes [46].
There are a few conflicting reports in CRC regarding the
clinicopathological significance of MVD, in which MVD is
not associated with tumour stage [29,43,47], vascular and
neural invasion [47], metastasis [29], or survival in the
whole group of patients [4,29,48,49], subgroups of
patients in stage A-C [47], or patients with stage I and II
rectal cancer [50]. In addition, there were four studies
which are performed on a small number of colon and/or
rectal cancers (from 22 to 48 cases) that also show a non-
association of MVD with the clinicopathological variables
including tumour size, location, grade of differentiation,
the presence of a mucinous component, stage, vascular or
lymphovascular or neural invasion, or patient survival
[30,51-53].
There are even opposite results from two studies in which
higher values of MVD appear to be in the early stages of
CRC [54], and correlate with longer disease-free survival
and overall survival in patients with node-negative CRC
[55]. Recently, Peeters et al. observed an increased vascu-
larization of metastases in the liver after resection of the
primary CRC [56]. This result suggests that the primary
tumour may produce certain circulating inhibitors of ang-
iogenesis that suppress the angiogenesis of metastases.
Therefore, after resection of the primary tumour, the circu-
lating levels of this inhibitor decrease, resulting in
increased angiogenesis and, as a consequence, growth of
the metastases [57].
Hypercoagulation in cancer patients is another factor for
tumour progression. Substantial evidence from preclinical
experiments and clinical practice has supported the asso-
ciation between activation of blood coagulation and pro-
gression of the cancer. Cancer patients display a wide
range of coagulation disorders from asymptomatic labo-
ratory changes to massive thromboembolism and dissem-
inated intravascular coagulation. About 50% of all cancer
patients and 90% of patients with metastasis have abnor-
malities in coagulation tests. CRC is the second most com-
mon cancer diagnosed in patients with thromboembolic
events. Blood vessel thrombosis leads to impairment of
blood flow, ischemia, and organ damage. The hemostatic
complications are the second most common cause of
death in cancer patients [58].
Studies have shown that plasma D-dimer levels, repre-
senting activation of coagulation and fibrinolysis, are
increased in most patients with CRC compared to patients
with benign colorectal disease. Furthermore, the D-dimer
level is positively related to tumour size, wall penetration,
lymph node invasion, and hepatic metastasis [59]. In a
multivariate analysis, the D-dimer level in preoperative
plasma in CRCs is the third strongest prognostic factor,
after lymph node status and preoperative carcinoembry-
onic antigen level [60]. Fibrinolytic capacity was much
higher in advanced CRCs, indicating a progression to
overt disseminated intravascular coagulation [58].
Although the mechanism behind hypercoagulation in
cancer patients is unclear, the main factor responsible for
hypercoagulation has been considered to be cancer itself.
It has been shown that tumour cells activate the coagula-
tion system by producing and secreting procoagulant/
fibrinolytic substances and inflammatory cytokines, as
well as physically interacting with blood (monocytes,
platelets, neutrophils) or vascular cells [61]. This activa-
tion is accompanied by the consumption and decline of
coagulation inhibitors. Other mechanisms for hypercoag-
ulation in cancer patients include non-specific factors
such as the generation of acute phase reactants, necrosis,
abnormal protein metabolism and hemodynamic com-
promise. In addition, anticancer therapy may also
increase the risk of blood coagulation by similar mecha-
nisms, e.g., release of procoagulant/fibrinolytic sub-
stances and inflammatory cytokines, damage of
endothelial cells, and stimulation of tissue factor produc-
tion by host cells [61].
A recent study shows that VEGF is highly expressed in pri-
mary CRC compared to the corresponding adjacent nor-
mal mucosa [62]. VEGF expression appears to be absent in
mild to moderate dysplasia adenomas of the colorectum,
and is present in the majority of carcinomas-in-situ and in
all carcinomas invading the submucosa [32]. VEGF-D is
more highly expressed in carcinoma than in the adjacent
normal mucosa [22,24] and adenoma [24], while VEGF-
C expression in normal mucosa does not differ from thatPage 3 of 20
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expression is significantly lower in both polyp and carci-
noma compared to normal mucosa while VEGF-A and
VEGF-C are significantly raised in carcinoma compared to
normal mucosa and polyp. One explanation for this is
that decreased VEGF-D may allow for higher levels of
VEGF-A and VEGF-C to bind more readily to the VEGF
receptors, producing the angiogenic switch required for
tumour growth [19].
Increased expression of VEGF-A in CRC is associated with
lymphatic metastases [19]. Increased VEGF-C expression
correlates significantly with poorer differentiation [28],
deeper invasion of tumours [28,63], advanced Duke's
stage [28], lymphatic invasion, lymph node metastasis
[28,63], venous invasion [28], and liver metastasis
[28,64]. VEGF-D is associated with lymphatic involve-
ment [24]. Overall, high VEGF expression is related to
larger tumour size [65,66], non-mucinous carcinoma
[27], advanced stage [65-67], blood vessel invasion, liver
metastasis [67], multiple numbers of metastases [55], and
recurrence [68].
There are few studies of VEGFR expression in CRC. Some
studies show that either VEGFR-2 or -3 expression on CRC
does not differ from that in the normal mucous of the
colorectum [19,22], while others show that VEGFR-3-pos-
itive vessel densities increase progressively from normal
mucosa to adenoma and to carcinoma [22,24,69]. Fur-
thermore, VEGFR-3 is associated with lymph node metas-
tasis [69].
There are controversial results regarding the role of VEGF
and VEGFR in CRC. For example, levels of VEGF expres-
sion in primary CRC and liver metastases do not signifi-
cantly differ [55]. VEGF-A has no impact on patient
survival [4]. VEGF-C is not related to gender, histological
type, venous involvement [63], lymph node invasion
[19], liver metastasis or survival [63]. VEGF-D and
VEGFR-3 expression do not correlate with grade of differ-
entiation, Dukes' stage (A to C) or survival [24].
Even splicing variants in certain members of the VEGF
family play different roles in tumour development. For
example, the VEGF-A gene, located on chromosome
6p21.3 with eight exons, gives rise to several distinct iso-
forms of VEGF-A through alternative mRNA splicing. The
more common isoforms of human VEGF-A consist of
VEGF121, VEGF145, VEGF165, VEGF165b, VEGF189,
and VEGF206, and other isoforms such as VEGF148,
VEGF162 and VEGF183 have also been reported. VEGF-B
also has different isoforms such as VEGF167 and
VEGF186 [70,71]. These isoforms differ in their expres-
sion patterns as well as their biochemical and biological
properties. In normal colonic tissue, VEGF121 and
VEGF165 are mainly expressed, whereas VEGF189 is
expressed rarely and weakly. VEGF121 and VEGF165 are
diffusible secreted proteins with low affinity to heparin,
whereas VEGF189 and VEGF206 have a high affinity to
heparin-like molecules such as heparansulfate [72].
Okamoto et al. examined the expression patterns of sev-
eral VEGF-A isoforms in 228 established xenografts origi-
nating from various human solid tumours including
colon cancer. VEGF121/VEGF165 were seen in 27
xenografts and VEGF121/VEGF165/VEGF189 in 201
xenografts. VEGF189 is more frequently expressed in all
tumour xenografts than in primary tumours, indicating
that VEGF189 contributes to the successful xenotrans-
plantability of various solid tumours through the induc-
tion of stromal vascularization [73]. Although the rate of
tumour growth depends on the level of VEGF expression,
certain isoforms play a greater role in angiogenesis than
others. VEGF165b inhibits VEGF165-mediated prolifera-
tion, migration of endothelial cells, and vasodilatation of
mesenteric arteries. VEGF165b-expressing tumours grow
significantly more slowly than VEGF165-expressing
tumours. Thus, VEGF165b is an effector of anti-angiogen-
esis and is downregulated in certain tumours. These
results suggest that regulation of VEGF splicing is a critical
switch from an antiangiogenic to proangiogenic pheno-
type [74,75].
Lymphangiogenesis in relation to clinicopathological variables
There are only a few studies of lymphatic density in CRC.
Parr and Jiang examined lymph vessel status by using sev-
eral lymphangiogenic markers (LYVE-1, Prox-1, podo-
planin and 5'-nucleotidase), and found that their
expression was higher in CRC compared to normal
mucosa [22]. In adenoma, lymphatic vessels in stalk
stroma were closely associated with early invasive epithe-
lial nests [76]. Recently, Kuroyama et al. observed that
intratumoural lymphatic vessels were present in the
majority of colon carcinomas (91%), and had a signifi-
cantly higher density in the submucosa near the tumour
[77]. Furthermore, intratumoural lymphatic density is
positively related to lymph node metastasis and arteriolar
density, but not to tumour size, depth of tumour invasion,
distant metastasis or TNM stage [77].
Like new blood vessels, lymphatics at the centre of
tumours do not function as well in spreading tumour cells
as they do at the invasive margin of tumour. The intratu-
moural lymph vessels are often compressed and smaller,
while the lymph vessels around tumours are often
enlarged and hyperplastic. These enlarged vessels may col-
lect tumour cells from the tumour and possibly contribute
to lymphatic metastasis. VEGF-C and VEGF-D induce not
only the density but also the enlargement of lymphatic
vessels, which leads to metastases to the regional lymph
nodes [78-80].Page 4 of 20
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increased in CRC, compared to normal mucosa and ade-
noma, and are further related to more malignant features
of CRC including poorer survival.
Inflammatory infiltration in CRCs
There are two types of immune responses, innate and
adaptive immunity. Innate immunity reacts rapidly to
molecular patterns found in microbes, independent of
prior contact with a pathogen. The adaptive immune
response is specific and has immunologic memory [81].
Immune responses play a critical role in host defence
against many kinds of diseases including tumours. In
immune responses against tumours, antigen-specific
receptors presented on lymphocyte surface membranes
recognize and specifically bind to the surface components
of the tumour cell [82]. Tumour inflammatory infiltration
(TII) mainly includes T cells and B cells (the adaptive
response), as well as tumour-associated macrophages
(TAM), dendritic cells (DCs), natural killer (NK) cells,
neutrophils, mast cells and eosinophils (the innate
response). The majority of TII cells are T cells, specifically
CD4+ and CD8+, and the anti-tumour effects of T cells are
considered to be mediated by cytokine secretion [83-85].
B-lymphocytes proliferating in the draining lymph node
migrate into the tumour where they undergo further
rounds of antigen-driven stimulation and proliferation,
resulting in antibody secretion. The antibodies bind to
tumours resulting in tumour destruction via phagocytes in
the presence of complement. NK cells are another group
of lymphocytes, and lack B-cell and T-cell receptors. NK
cells are designed to kill certain mutant cells and virus-
infected cells, by releasing proteolytic enzymes called
granzymes, pore-forming proteins called perforins and
chemokines. Granzymes pass through the pores and acti-
vate the enzymes that lead to apoptosis of the infected
cells by means of destruction of their structural cytoskele-
tal proteins and by chromosomal degradation. As a result,
the cells break into fragments that are subsequently
removed by phagocytes. Perforins can also sometimes
result in cell lysis. TAMs derive from circulating monocytic
precursors, and are directed into the tumour by chemoat-
tractant cytokines called chemokines. Tumour cells also
produce cytokines that can prolong the survival of TAMs
[86]. TAMs can kill and phagocytose tumour cells and
remove apoptotic and necrotic tumour cells [87] by secret-
ing lytic enzymes such as lysosomal enzymes, TNF-α and
macrophage activation factor [82,88]. TAMs can also serve
as antigen presenting cells, which evoke a strong immu-
nologically mediated response [86,87,89]. DCs are a
unique group of white blood cells and are present in a
basically immature state. After taking up and processing
antigen, DCs migrate to the lymphoid tissues where they
interact with T cells and B cells to initiate and shape the
immune response. DCs also activate non-specific effectors
such as macrophages, NK cells and eosinophils [90].
The TII response may have dual effects in the develop-
ment and progression of the tumour. On one hand,
inflammatory cells can kill tumour cells, resulting in
tumour regression and a greater chance of survival for the
cancer patient. On the other hand, production of
cytokines and growth factors derived from TII can stimu-
late tumour cells to grow and emigrate. The effects on
tumour development may depend on host- and tumour-
specific features such as the immunoresponse of the host
or the type and biological features of the tumour [91-93].
For example, TAMs have tumour inhibitory effects as
mentioned above, but also have tumour promoting
effects. TAMs produce growth and angiogenic factors such
as TNF-a, IL-1 b, IL-8, fibroblast growth factor, VEGF, epi-
dermal growth factor [94] as well as protease enzymes
which degrade the tumour ECM. Hence, TAMs stimulate
tumour-cell proliferation, promote angiogenesis, and
favour invasion and metastasis.
Lymphocytic infiltration in relation to clinicopathological variables
Many studies have shown that a high grade of lym-
phocytic infiltration or TII in CRC is related to favourable
survival of patients [95-106], and the prognostic signifi-
cance of the TII still remains even after adjustment for
other clinicopathological variables in the whole group of
CRC patients [107-115], patients with T1-2N0M0 or
T3N0M0 CRC [89], with T1N0-3M0 or T1-4N1-3M1
[116], or stage II-III [44]. In addition, an extensive TII is
related to better differentiation of tumours [99], earlier
stage [99,110,116,117], lower rates of recurrence [96,103]
and distant metastasis [103]. There are several possible
explanations for the TII in relation to better survival and
less malignant features in cancer patients. Firstly, the TII
could represent a specific response by the host against the
tumour. Secondly, the TII may function as a barrier for
tumour penetration [112], and thirdly, tumours with
extensive TII may respond better to chemotherapy. Our
recent study showed that younger patients have more TII
around rectal cancers, suggesting that younger patients
had a better immunological response than older ones
(unpublished data). However, there are controversial
reports in which TII is not related to tumour differentia-
tion, stage [97-117] or patient survival in CRCs [118]. In
addition, TII is not associated with patient' gender,
tumour location, or growth pattern [97-110]. One study
shows that CD8+ T cell and macrophage infiltration are
negatively related to the depth of invasion and vascular
invasion [100].
Notably, TII in the inner part of the tumour is not signifi-
cantly related to clinicopathological variables including
patient survival, but abundant TII at the invasive marginPage 5 of 20
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patients [110]. These results indicate that TII at the inva-
sive margin, compared with that in the inner part of
tumour, is more effective against tumour development.
Obviously, attention to the tumour invasive margin, not
only to its morphology but also to its biology, is an impor-
tant issue regarding tumour development and progres-
sion. Tumours with an infiltrative growth pattern at the
invasive margin present a strong malignant phenotype
and further predict a poor prognosis in CRC patients com-
pared to tumours with a expansive growth pattern
[66,119]. It has been observed that either expression of
PINCH or phosphatase of regenerating liver (PRL) at the
invasive margin of CRC is related to a poor prognosis,
while their expression in the inner parts of the tumour is
not [110,120]. The invasive margin is a critical area for
stimulation of angiogenesis and lymphangiogenesis in
tumours, which contributes to tumour invasion and
metastasis. Dundas et al. have analysed 60 slides from 60
tissue blocks from 30 colonic carcinomas, and the slides
are circulated twice to six histopathologists with varying
experience [121]. Five out of the six pathologists showed
a good to excellent intraobserver agreement for assess-
ment of the character of the invasive margin, which is not
significantly affected by sampling. The pathologists were
not reliable in assessing peritumoural lymphocytic infil-
trates, and this assessment was significantly affected by
sampling. The results indicate that peritumoural lym-
phocytic infiltration is not a reproducible observation and
may therefore not provide useful prognostic information
in routine practice.
TAMs in relation to clinicopathological variables
TAMs are highly localized at the invasive margin of CRC
compared with the central area of the tumour
[44,122,123]. Furthermore, the number of TAMs in the
invasive margin positively correlates with the degree of
lymphocytes and apoptotic cancer cells [87,122,123].
CRC patients with a high TAM level have significantly less
invasion in depth [100], lymph node [100,124] and
blood vessel [100], and less local and distant recurrence
[103,124]. Moreover, abundant TAMs are a sign for better
survival of CRC patients [100,103]. In some studies, TAMs
are even an independent prognostic factor of good sur-
vival [44,89]. One study shows that the presence of TAMs
in regional lymph node metastases may serve as a predic-
tor of better survival in patients with CRC of Dukes' stage
C [125]. Taken together, the results suggest that TAMs are
effective in inducing apoptosis of tumour cells and sup-
pressing tumour spread at the front line of host defence,
thereby inhibiting tumour development.
It has been shown that TAMs are positively associated
with angiogenesis in CRC [94]. Such an association is also
seen in liver metastasis from CRC, furthermore both
TAMs and MVD independently predict worse prognosis
[126]. However, some studies do not find associations of
TAM numbers with microvessels [44,127], or any clinico-
pathological features including depth of invasion, stage,
lymph node metastasis, vascular invasion, recurrence and
prognosis [55,127]. FasL+ macrophages may also induce
apoptosis of neighbouring Fas+ lymphocytes, which may
explain a negative regulatory mechanism of TAMs against
T cells distributed in the same areas [123,127].
DCs in relation to clinicopathological variables
Patients with CRC present reduced numbers of peripheral
blood DCs compared with healthy controls [128]. Fur-
thermore, the number of DCs is decreased in primary
colon cancer compared with the normal colon mucosa
[129] and is even less in lever/pelvic metastasis, six-fold
lower than in primary CRC [130]. DCs are often present
in the invasive margin of both primary and metastatic
CRC [131-133]. DCs positively correlate with lymphocyte
infiltration [131,132,134], but inversely correlate with
levels of serum VEGF [128,135], probably because of the
inhibition of VEGF on DC maturation in tumours [136].
Most studies in CRCs have shown that abundant DCs, fre-
quently determined by DC markers of S-100, CD83 or
CD86, are associated with less depth invasion [137], less
lymph node involvement [137,138], less liver metastasis
[128,137,138] or better survival [130,131,134,137,138].
A study performed on liver metastasis from CRC has
shown that DCs determined by CD83 are positively
related to apoptotic cancer cells, and independently pre-
dict a better prognosis [133]. These results indicate that
DCs may act as one line of defence against tumour devel-
opment of primary and metastatic CRC.
A study in 170 patients with rectal cancer using CD1a as a
marker for DCs did not find that DCs are related to sur-
vival [48]. Notably, Sandel et al., using markers CD1a and
CD208 for DCs in CRC, found that patients with high lev-
els of either CD1a- or CD208-positive DCs had shorter
survival [139]. However, the same group carried out
another study on the same series of CRCs using the S-100
marker for DCs, and demonstrated that the presence of
TAMs was a prognostic factor for better survival [134].
Since the same group studied the same patients using the
same technique, the reason for the different results would
not be due to sample error, method variation, or features
of tumours or patients. It has been observed that CD83-
positive DCs in the invasive margin form clusters with
lymphocytes. Although the number of CD1a-positive DCs
are almost the same as that of CD83-positive DCs in the
invasive margin of the tumour, CD1a-positive DCs are
mostly scattered and rarely form clusters with lym-
phocytes. DCs that express both CD1a and CD83 are rare
[132]. The distinct infiltration pattern of DCs in tumours
indicates various biological functions of DCs. In otherPage 6 of 20
(page number not for citation purposes)
Molecular Cancer 2006, 5:43 http://www.molecular-cancer.com/content/5/1/43words, these conflicting results regarding the role of DCs
on CRC prognosis may partly depend on the different
markers used in the different studies; for example, DCs
that are determined by markers S-100 and CD83 often
appear to be related to an immuno response with antitu-
mour activity. Therefore, it could be of interest to study
molecular issues of DC heterogeneity in order to identify
unique biological functions in cancer development.
TII in CRC, especially at the invasive margin of tumours,
plays a critical role against tumour development and
aggressiveness, based on the relationship of strong TII
with better differentiation, earlier stage, lower rates of
local/distant recurrence and better survival.
MMPs in CRCs
MMP expression and biological functions
Cell adhesion to the ECM is mediated by integrins. Focal
adhesion (FA) is an integrin-rich cell adhesion sites, con-
taining cytoskeletal signalling molecules including FA
kinase, integrin-linked kinase (ILK), talin, vinculin and
paxillin. ILK is an intracellular serine/threonine protein
kinase regulating integrin-mediated cell adhesion, E-cad-
herin expression, pericellular fibronectin matrix assembly
and cellular proliferation and survival [140-142].
Through FA a selective group of cytoskeletal and signal-
ling proteins are recruited to cell matrix contact sites
where they link the actin cytoskeleton to the ECM and
where signals are transduced bidirectionally between the
intracellular signalling network and the ECM [143]. The
cell microenvironment and cell interactions with ECM
play an essential role in many physiological and patho-
logical processes. The ECM can actively regulate cellular
proliferation, migration, adhesion and invasion, which
influence embryonic development, tissue morphogenesis
and angiogenesis as well as tumour transformation and
metastasis. Tumour development is characterized by a
severe aberration in the interaction of tumour cells with
surrounding ECM.
During tumour progression, tumour cells must remodel
the matrix either by expressing or degrading ECM proteins
to facilitate communication and escape control by the
microenvironment. The remodelling of the microenviron-
ment surrounding tumour cells leads to the release of
ECM-associated growth factors which may function to
suppress or induce tumour growth [144]. Thus, many
ECM-associated factors are proposed to be involved in the
interaction of tumour cells with the ECM during tumour
progression.
MMPs are a family of ECM degrading proteinases, secreted
by both tumour and stromal cells. Based on substrate spe-
cificities and sequence characteristics, the classic MMP
family members can be divided into at least four sub-
groups; collagenases, gelatinases, stromelysins, and matri-
lysins. So far, 23 different MMPs, MMP-1, -2, -3, -5, -7, -8,
-9, -10, -11, -12, -13, -14, -15, -16, -17, -18, -19, -20, -21,
-23, -25, -26, and -28, and four tissue inhibitors of metal-
loproteinases (TIMPs), TIMP-1, -2, -3 and -4, have been
cloned [145-147]. MMPs play a major role in physiologi-
cal and pathological processes such as embryonic devel-
opment, differentiation, apoptosis, immune surveillance,
wound healing, tumour angiogenesis and invasion and
metastasis [148]. For instance, MMPs can cleave inter-
leukin-2 receptor (IL-2R), an upregulator of T lymphocyte
proliferation [149], and can activate TGF, an important
inhibitor of the T-lymphocyte response against tumours
[150], thereby suppressing the anti-tumour activity of T
lymphocytes. MMPs are also important for endothelial
invasion occurring during neovascularization. Applica-
tion of a blocking peptide that prevents the interaction of
MMP2 with its substrates has been shown to reduce ang-
iogenesis. When tumour cells are introduced into MMP2
knockout mice, the tumours that develop are less vascu-
larized and exhibit reduced growth compared to the
tumours in wild-type animals [151].
Unlike classical oncogenes, MMPs are not upregulated by
gene amplification or activating mutations, and the
increased MMP expression in tumours is probably due to
transcriptional changes. This might be the result of activa-
tion of oncogenes or loss of tumour suppressors. It has
been demonstrated that MMP7 is upregulated by the tran-
scription factor PEA3, and MMP1 and MMP13 are down-
regulated by the tumour suppressor p53 [152-154]. The
enzymatic activity of the MMPs may be blocked specifi-
cally by TIMP-1 and TIMP-2. The balance between the
MMPs and the TIMPs is thought to play a critical role in
controlling ECM turnover and in maintaining matrix
homeostasis.
MMPs in relation to clinicopathological variables
Among MMPs, MMP-1, -2, -3, -7, -9, -11, and -13 have
been studied the most. Expression of MMPs, such as
MMP-1, -2, -3, -7, and -9, is greater in CRC than in normal
mucosa or in adenoma of the colon/rectum [155-167].
Higher levels of MMP-7 expression are also found in liver
metastases compared with normal liver tissue [167].
However, there are a few reports showing inconsistent
results on expression of MMPs in CRCs. For example,
Roeb et al. have reported that expression of MMP-3 and -
13 is greater in CRC but MMP-1 expression is not [165].
Bodey et al. have observed strong expression of MMP-3
and -10 in colon cancers but not MMP-13 [168]. Unlike
other classical MMPs, MMP-19, -26, and -28 express in the
normal intestine, but are downregulated in colon cancer.
Thus, it has been proposed that they play a prominent role
in tissue homeostasis [169].Page 7 of 20
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most findings have shown that increased expression of
MMPs is related to more malignant features of CRCs.
MMP-1 correlates with poor differentiation [155],
advanced Dukes' stage, lymphatic invasion [155,161],
hematogenous metastasis [155], and shorter survival
[170]. MMP-2 expression is increased in CRC with infil-
trative growth patterns compared with expansive growth
patterns, and it has positive relationships with poor differ-
entiation [171] and liver metastasis [172]. MMP-3 has
been found to be associated with lymph node metastasis
[159]. MMP-7 correlates with poor differentiation [163],
depth of invasion, lymphatic involvement [95], advanced
Dukes' stage [95,163], metastasis [95,173,174], and unfa-
vourable survival [95]. Even in multivariate analysis, the
prognostic significance of MMP-7 still remains [95,173].
MMP-9 is related to the presence of perineural invasion
[159]. MMP-13 overexpression tends to predict a poor
prognosis in patients with CRC [175]. Interestingly, Beh-
rens et al. have found that hereditary nonpolyposis color-
ectal cancer syndrome (HNPCC) exhibited a significantly
lower expression of MMP-1 and -9, whereas sporadic
CRCs usually have increased expression of MMPs. These
findings on the basis of lower matrix-degrading properties
of the fibroblastic tumour stroma in HNPCC may help us
to understand why HNPCC, compared with sporadic
CRC, has lower malignancy, for example, a better progno-
sis in HNPCC patients [156].
During tumour invasion and metastasis, tumour cells
must pass a series of basement membrane and ECM barri-
ers. The basement membrane is the first and most impor-
tant barrier for tumour cells to penetrate to complete
invasive and metastatic processes. The ECM must be bro-
ken down to permit tumour cells to invade surrounding
tissues or metastasise to other organs. Furthermore, some
MMPs stimulate angiogenesis for promoting tumour
growth and invasion. Although the mechanism by which
MMPs enhance the invasive and metastatic competence of
tumour cells seems straightforward, the specific role of
distinct MMPs in the progression of tumour invasion and
metastasis is more complex than has been assumed. For
example, MMP-2 does not show an association with
tumour differentiation, stage, metastasis, or patients'
prognosis [157]. Oppositely, MMP-2 level in plasma is
higher in T2 and T3 CRCs than T4 tumours [161]. MMP-
9 expression has no link to either tumour stage or patients'
survival [171]. CRC patients with overexpression of MMP-
12 have a better prognosis compared with patients who
do not show overexpression of MMP-12. Some of the
MMPs, such as MMP-2, can convert plasminogen to angi-
ostatin, which is a potent inhibitor of endothelial cell pro-
liferation and angiogenesis [176,177]. Therefore, these
MMPs may limit angiogenesis, inhibit tumour growth and
suppress metastasis.
We found that ST3 (MMP11) is positively related to
PINCH expression in CRC (unpublished data), and, both
ST3 and PINCH are present in stromal fibroblasts around
tumour cells but not in tumour cells themselves
[178,179]. The ST3 gene is localized to chromosome
22q11.2, with 8 exons and 7 introns [180,181]. The term
"stromlysin-3" is chosen because the protein has the same
four-domain structure as previously described stromlysins
and because "stromlysin" is correlated with ST3 RNA
expression in stromal cells of breast cancer [182]. ST3
belongs to a new MMP subfamily according to its gene
location, the sequence of the putative ST3 catalytic
domain, and function. ST3 differs from those reported
MMP genes on chromosomes 11, 16, and 19 [182], as the
ST3 prodomain contains an additional recognition site for
convertase-like enzymes such as furin. Consequently, the
ST3 proenzyme, unlike other MMPs, is processed intracel-
lularly and released as a mature enzyme [183]. Unlike
most of the MMPs, which are activated outside the cell by
other MMPs or serine proteinases, ST3 can also be acti-
vated inside the cell by intracellular furin-like serine pro-
teinases [151,184].
Although the exact mechanism of ST3 action is unknown
in tumour development, one hypothesis is that ST3 is
implicated in basement membrane remodelling through
release or activation of growth factors or cytokines stored
in the ECM. ST3 degrades insulin-like growth factor-bind-
ing protein-1 (IGFBP-1), leading to cellular proliferation
and survival [185]. It has been shown that cancer cells
injected into ST3-null mice have an increased frequency
of apoptosis and necrosis compared to the wild-type hosts
[186]. ST3 inhibiton of apoptosis may be through the
release of survival factors such as insulin-like growth fac-
tor (IGFs) [187]. ST3 is also involved in the escape mech-
anisms of TII, and decreases the sensitivity of tumour cells
to NK cells [178], but positively regulates tumour angio-
genesis [188]. Thus, ST3 may play a role in favouring can-
cer cell survival in the stromal environment during
tumour development.
ST3 protein is present in the stromal fibroblasts around
tumour cells but not in tumour cells themselves. ST3
expression, determined by Northern blot, in-situ hybridi-
sation or immunohistochemistry, is undetectable in nor-
mal colorectal mucosa, detectable in low levels in
adenoma, and at higher levels in primary CRC [178,189-
194] and in metastasis of the lymph node and the liver.
However, there is no significant difference in the levels of
ST3 expression between the primary and metastatic
tumours [178,189,193], or between the inner part and
invasive margin of CRC. This indicates that a high degree
of ECM turnover also takes place at the inner part of the
tumour, and not only at the invasive margin wherePage 8 of 20
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[190].
The rate of extensive ST3 expression is significantly higher
in the de novo group than in the ex adenoma group. His-
topathologically, the de novo group has a significantly
higher rate of cases with an infiltrative invasion pattern.
These results may indicate that ST3 expression is impli-
cated in a greater invasive potential of CRC [192]. As
shown in Figure 1, tumour with an infiltrative growth pat-
tern has higher ST3 expression than that with an expand-
ing growth pattern [178,194]. However, ST3 is highly
expressed in Dukes A+B tumours compared to Dukes C+D
tumours [178]. Taken together with similar levels of ST3
expression between the primary and metastatic tumours,
it seems that ST3 is involved in the local invasion and
early development of CRC, but is not a critical factor in the
late stage of CRC development although one study shows
that high expression of ST3 transcripts correlate with the
progression of CRCs toward liver metastasis [189].
Another study shows that ST3 expression is higher in
women than in men, and in distal tumours than in prox-
imal tumours in CRC [178]. ST3 expression is not related
to age, grade of differentiation, TII, the degree of tumour
invasion, metastases or survival in CRC patients
[178,190].
The MMP family is likely to be involved in early develop-
ment of CRC via remodelling of the basement membrane,
inhibition of tumour cell apoptosis and the host immune
response, and angiogenesis activation. MMPs also play
critical roles in tumour aggressiveness based on their rela-
Expression of ST3 in primary colorectal adenocarcinomas by immunohistochemistry performed on paraffin-embedded tissue sections counterstained with hematoxy inFigure 1
Expression of ST3 in primary colorectal adenocarcinomas by immunohistochemistry performed on paraffin-embedded tissue 
sections counterstained with hematoxylin: A) stromal cells of a tumour with an expanding growth pattern show negative 
expression, and B) stromal cells of a tumour with an infiltrative growth pattern show positive expression.
A
BPage 9 of 20
(page number not for citation purposes)
Molecular Cancer 2006, 5:43 http://www.molecular-cancer.com/content/5/1/43tionships with advanced tumour stage, high frequency of
recurrence and worse prognosis. However, MMPs can also
suppress tumour growth, invasion and metastasis.
PINCH expression in CRCs
PINCH expression and its biological functions
PINCH was originally identified by Rearden in 1994 from
screening a human cDNA library with antibodies recog-
nizing senescent erythrocytes [195]. The PINCH gene is
located on chromosome 2q12.2, and encodes a 38 kDa
protein. PINCH is an evolutionarily conserved adapter
protein and has five LIM domains [195-199]. Adapter pro-
teins, a group of non-catalytic proteins, are involved in
specific protein-protein interactions, which mediate
essential cellular processes including cellular prolifera-
tion, differentiation and survival by controlling signal
transduction pathways. The LIM domain is a protein
binding motif consisting of a cysteine-rich consensus
sequence of approximately 50 amino acids folding into a
specific three-dimensional structure comprising two zinc
fingers. LIM domains are present in nuclear and cytoplas-
mic proteins that are essential for embryonic develop-
ment and are involved in many pathological processes
including tumourigenesis [198,200-202].
PINCH interacts directly with ILK through its LIM1
domain binding to the first of four ankyrin (ANK) repeat
domains at the ILK N-terminus. The C-terminal domain
of ILK has certain homologies with the catalytic domains
of serine/threonine protein kinases. This kinase-like
domain is able to interact with several components of cell-
matrix contact sites including CH-ILKBP (α-parvin,
actopaxin), β1, β2, and β3 integrin cytoplasm tails, β-
parvin (affixin), and paxillin [203-207]. PINCH, ILK and
CH-ILKBP form a ternary complex that can interact with
other components of the cell-ECM adhesion structures via
multiple mediated interactions and therefore play crucial
roles at ECM adhesion sites [208]. The importance of this
complex has been emphasized by a number of research
groups. For example, overexpression of the N-terminus of
PINCH or the N-terminus of ILK results in retarded cell
spreading and reduced cell motility. The interaction of
PINCH and ILK is crucial for cell shape regulation and
migration via integrin activation. Inhibition of formation
of the PINCH-ILK-CH-ILKBP complex leads to a signifi-
cant reduction in fibronectin matrix deposition and inhi-
bition of cell proliferation [209,210].
PINCH can also bind to Nck2, an additional PINCH bind-
ing partner, through the LIM4 domain of PINCH and the
SH3 domain 3 of Nck2. Nck2, as an SH2/SH3 adaptor
protein, is an important component of the signalling
pathways of growth factor receptors including epidermal
growth factor (EGF) and PDGF receptors, and can modu-
late actin dynamics by interacting with p21-activated
kinase. Therefore, PINCH, by mediating the formation of
the complex between ILK and Nck-2, is involved in the
regulation of ILK function, which is implicated in many
critical physiological and pathological processes
[179,197,209-211].
Zhang et al. identified a second member of the PINCH
family, PINCH2, and therefore, PINCH was renamed to
PINCH1 [208]. The PINCH2 gene has been mapped to
chromosome 2q14.3 and encodes a 39 kD protein. The
PINCH2 protein also contains five LIM domains and has
an overall similarity of 92% to PINCH1. At the embryonic
stage, PINCH1 is expressed in the heart, lung, kidney,
liver, thymus, spleen, bladder, stomach, intestine, skeletal
muscle and facial regions especially surrounding skeletal
structures, while PINCH2 expression is restricted to the
bladder, stomach and intestine. In the intestine, PINCH1
expression is localized to epithelial cells and the smooth
muscle layer, whereas PINCH2 expression is confined to
the smooth muscle layer. In addition, high expression of
PINCH1 is present in megakaryocytes during fetal liver
hematopoiesis, where PINCH2 expression is undetecta-
ble. Megakaryocytes also express ILK and Nck2, the
known binding partners of PINCH1. In adults, both
PINCH1 and PINCH2 are expressed in the heart, lung,
kidney, liver, bladder, uterus, testis, skin, skeletal muscle,
large intestine and fat. In the spleen and thymus, only
PINCH1 transcripts are present. Similarly to the embry-
onic intestine, PINCH1 expression is observed in the epi-
thelial cell layer of the intestine and in the surrounding
smooth muscle cells, whereas PINCH2 is confined to the
smooth muscle layer [200].
PINCH2 also localizes to cell-ECM adhesion sites but only
the LIM1 domain binds to ILK, suggesting that PINCH2
may potentially interact with other components of the
cell-ECM adhesion structure. In addition to regulating the
PINCH1-ILK interaction, cell spreading and migration,
PINCH2 may participate in the regulation of nuclear proc-
esses since PINCH2 is present at high levels in the nucleus
of the cell [200]. However, PINCH2 does not bind to Rsu-
1 as PINCH1 does. Rsu-1 is a highly conserved leucine-
rich repeat protein and expresses in various mammalian
cells. Ectopic expression of Rsu-1 inhibits anchorage-inde-
pendent growth of Ras-transformed cells and some
human tumour cell lines [196].
PINCH in relation to clinicopathological variables
After identifying the PINCH gene, Rearden's group in
2002 further analysed PINCH protein expression deter-
mined by immunohistochemistry using a polyclonal anti-
body against PINCH in human tissues, and observed that
PINCH expression was markedly upregulated in the
tumour-associated stroma of many common cancers
including breast, prostate, lung, skin, and colon cancers,Page 10 of 20
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shown in Figure 2, PINCH is noted to be especially abun-
dant in stromal cells at the invasive margin of the tumour,
a region where signalling in the integrin and growth factor
pathways is known to occur. Recently, we have further
studied the clinicopathological significance of PINCH
expression in a large series of CRCs by immunohisto-
chemistry using the same antibody used in the above
study. Our results show that the expression of PINCH pro-
tein in the stroma is not only increased in primary
tumours compared to normal mucosa, but is also signifi-
cantly increased in lymph node metastasis compared to
primary tumours, and is more intense at the invasive mar-
gin than in the intratumoural stroma. Strong PINCH
expression at the invasive margin of primary tumours is
further related to lymph node metastasis and predicts a
worse outcome in the patients, independent of Dukes'
stage, growth pattern and grade of differentiation
[179,212].
The intensity of PINCH expression in the inner part of pri-
mary tumour is not significantly related to survival and
other clinicopathological variables including Dukes'
stage, growth pattern and grade of differentiation [179].
Localization of the PINCH protein seems to be very criti-
cal for its function in tumour development and aggres-
siveness. That is, PINCH expression at the tumour
invasive margin, but not in the inner part of the tumour,
plays an important role in tumour aggressiveness.
The PINCH protein is detected not only in fibroblasts, but
also in myofibroblasts and in a proportion of endothelial
cells of the tumour vasculature (whereas normal epithelial
and tumour cells do not show any staining) supporting
Expression of PINCH in primary colorectal adenocarcinoma by immunohistochemistry performed on a paraffin-embedded tis-sue s cti  counterstai ed with hematoxylinFigure 2
Expression of PINCH in primary colorectal adenocarcinoma by immunohistochemistry performed on a paraffin-embedded tis-
sue section counterstained with hematoxylin: expression of PINCH protein at the invasive margin (arrow) was much stronger 
than in the inner tumour area.Page 11 of 20
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interactions that support tumour progression [179,212].
PINCH expression has been found to be oppositely asso-
ciated with TII, suggesting that the upregulation of PINCH
may be the tumour-activated reaction against TII, leading
to tumour progression. Myofibroblasts have been consid-
ered to be associated with desmoplastic stromal tumour
responses, and proposed to form a barrier to the migra-
tion of immunocompetent cells toward the tumour and
hence to reduce immune surveillance. TII is known to
reflect of the tumour-associated immune response and is
generally considered to be cytotoxic for the tumour cells
[95,116]. A previous study in colon cancer showed a neg-
ative correlation of the presence of myofibroblasts with
TII [213]. The presence of PINCH in endothelial cells of
the tumour vasculature suggests that the PINCH protein is
upregulated in tumour angiogenesis, which is particularly
important and indispensable for tumour growth and
metastasis.
The adapter protein PINCH, a new component of the cell-
ECM adhesion structure, may have an important role in
tumour invasion and metastasis, via tumour-stromal
interactions, resulting in a poor prognosis. It is of interest
to further study the biological and clinicopathological sig-
nificance of PINCH 1 and PINCH2 in tumours.
Stroma and cancer therapy
Although conventional chemotherapy and radiotherapy
have improved the outcome for CRC patients, the benefits
of the treatments are still under investigation, especially in
patients with advanced-stage tumours. The side effects of
the treatments and resistance to the treatments are still
major problems. Because of a lack of specific markers to
select patients for suitable treatments many patients have
been overtreated by chemotherapy and radiotherapy.
Thus, biomarkers for both tumour cells and stroma are
urgently needed to complement current tumour stage in
terms of response to treatments. Compared to tumour
cells, the stroma has been shown to be a more attractive
therapeutic target. Firstly, regulation of stromal activity
could affect tumourigenesis in different ways including
inhibition of angiogenesis, lymphangiogenesis and MMP
activity as well as activation of certain TII, to stabilize and
regress the primary tumour. Secondly, some stromal fac-
tors, such as endothelial cells, are highly accessible to cir-
culating drugs or drug carriers [214]. Thirdly, the optimal
dose for conventional cytotoxic anticancer agents has usu-
ally been defined as the maximum tolerated dose. In con-
trast, biological and antiangiogenic agents may achieve
maximum therapeutic effect at doses below the maximum
tolerated dose. Therefore, it is important to assess quanti-
fiable effects on the molecular target or biological param-
eters downstream from the molecular target, as well as
safety end points to establish the dose-effect relationship
and determine both the optimal biological dose and the
maximum tolerated dose [3]. Fourthly, stromal cells,
compared to tumour cells, are less likely to develop drug
resistance; although some stromal proteins are tumour-
derived, most stromal proteins are the products of stromal
cells. Finally, one of the major problems with conven-
tional radio- or chemo-therapies is that they indiscrimi-
nately affect growing normal and tumourigenic tissue;
therefore, a therapy targeted to the stroma would mini-
mize the side effects of anti-cancer therapy [8].
Antiangiogenic therapy
Antiangiogenic therapy is a new promising strategy for
inhibiting tumour growth, development and metastasis. A
number of potential angiogenic inhibitors have been
developed to affect endothelial cell proliferation, migra-
tion and survival, and some of these agents have entered
clinical trials in CRC patients. PTK/ZK acts on VEGFR-1, -
2 and -3, SU 11248 on VEGFR-1, -2, -3 and PDGFR, ZD
6474 on VEGFR-1, -2, -3 and EGFR, BAY 43–9006 on
VEGFR-2, -3 and PDGFR, AEE 788 on VEGFR-1, -2 and
EGFR, Imatinib on PDGFR, and gefitinib and erlotinib on
EGFR [215]. Among the VEGFR family, the VEGFR-2/
kinase-insert-domain containing receptor is upregulated
during tumourigenesis. An anti- kinase-insert-domain-
containing receptor antibody, IMC-1C11, blocks VEGFR-
kinase-insert-domain containing receptor interaction, and
inhibits VEGFR-induced endothelial cell proliferation.
There are two new monoclonal antibodies, bevacizumab
(Avastin) targeting VEGF, and cetuximab targeting EGFR,
which have been used for treating CRC patients with
metastasis. Bevacizumab has been shown to improve pro-
gression-free survival and overall survival of metastatic
CRC patients for both first-line and second-line combined
treatments with irinotecan, fluorouracil/leucovorin or
oxaliplatin [215]. It has been demonstrated that bevacizu-
mab increases the activity of fluorouracil/leucovorin in
the first-line treatment. Cetuximab directly inhibits EGFR
by binding its extracellular region and blocking ligand-
receptor interaction, thus preventing downstream signal-
ling events. Data from several phase II trials have shown
that the combination of cetuximab with fluorouracil/leu-
covorin plus irinotecan or fluorouracil/leucovorin plus
oxaliplatin with irinotecan leads to a high response rate, a
long time to progression, and a good prognosis in the
first-line treatment of metastatic CRC. Panitumumab, a
monoclonal antibody against EGFR, has also shown to be
active in irinotecan and oxaliplatin-refractory metastatic
CRC [216]. The accumulated data from preclinical exper-
iments and clinical trials have led to the design of trials
look at the activity of angiogenic inhibitors in combina-
tion with cytotoxic regimens, with the hope of further
improving the outcome for patients with metastatic CRC
[216].Page 12 of 20
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Immunotherapies, as less toxic treatment modalities, have
emerged as potentially attractive alternatives for cancer
therapy. It has been shown that when patients with resect-
able recurrent CRC are treated with interleukin-2 before
surgery, there is an increase of eosinophilic infiltration in
tumour tissue, indicating that interleukin-2 increases the
host response to the tumour [217]. In another study, OK-
432, an immunomodulatory agent prepared from an
attenuated strain of Streptococcus pyogenes, was injected
intratumourally in patients with CRC. Postoperative
examination revealed the formation of fibrin fibers at the
site of injection, and further marked TII cell infiltration
including many giant cells in the tumour stroma, leading
to extensive regression of the tumour [218].
MMPIs
MMPIs, such as BAY12–9566, AG3340, BMS275291 and
CGS27023A/MPI270, have been shown to inhibit tumour
growth in preclinical models. However, this treatment has
achieved minimal success in patients with advanced can-
cers in clinical trials. The differences between preclinical
and clinical results with MMPIs are not just due to differ-
ences between animal and man but are rather related to
the stage of disease, different endpoints, and the treat-
ment methods. For example, MMPIs are unlikely to be
effective in patients with advanced-stage cancer. However,
there are significant preclinical data to support a role for
MMPIs in earlier stages of cancer. In addition, MMPIs are
used to treat patients with endpoints of increased time to
progression or improved outcome. In comparison, pre-
clinical experiments performed in animals is to examine
tumour progression with the final endpoints of reduced
tumour number and size or metastasis. Finally, patients
are given the maximum tolerated dose and this is often
limited by musculoskeletal side-effects while animal stud-
ies used escalating doses of MMPIs that are not limited
since mice are less susceptible to this side-effect. Thus, it is
of importance to design MMPIs for selected patients. It is
also important to select MMPIs-1, -3, -7, -9, and -13 as
potential agents, since the expression of the correspond-
ing MMPs correlates with metastasis and poor prognosis
in cancer patients. Moreover, MMPs have a dual function
in tumour development; namely, they play critical roles
not only in tumour aggressiveness but also in suppression
of tumour growth. This complicates treatment targeting
MMPs. Based on accumulated data, it is recommended
that future MMPI trials focus on: (1) patients with early
stage cancer; (2) the use of MMPIs along with chemother-
apy; (3) the measurement of MMPs in tumour tissue and
blood as a means of identifying patients who are more
likely to respond to MMPI therapy; and (4) identification
of biomarkers that reflect activation or inhibition of
MMPs in vivo [219].
MMPs have been suggested as biomarkers for selecting
cancer patients for suitable treatments. Ogata et al. exam-
ined patients with CRC at stage II or III, who underwent
potentially curative resection. The patients were divided
into two groups: one group received postoperative admin-
istration of fluoropyrimidines (such as UFT and 5'-
DFUR), and the other group underwent surgery alone.
The disease-free survival rate in the chemotherapy group
was significantly higher than that of the surgery-alone
group. However, this difference was not seen between the
two groups who had MMP-9 positive tumour. Thus, the
efficacy of the chemotherapy may not be great for patients
with a tumour positive for MMP-9 [220].
Although there are promising results in the treatment of
cancer patients with immunotherapy, anti-angiogenesis
and MMPIs, the roles and effects of these treatments are
still under investigation. An important challenge is how to
combine biological agents with different cytotoxic agents
in CRC. Another important challenge is to combine ther-
apeutic targets of tumour cells with those of stromal fac-
tors.
Conclusion
It has been suggested that CRC is caused by both environ-
ment, including life style, and genetic predisposition. In
general, the number of genetic alterations is increased
from the first genetic change in a normal endothelial cell
to several genetic alterations in the late stages of cancer
cells. Moreover, in the tumour stroma, the number and
construction of blood and lymph vessels are altered by
stimulation with many stromal factors such as VEGF,
VEGFR, TII, MMP, PINCH, and others. Interactions
between these growth and anti-growth stromal factors in
the tumour stroma affect the formation, development and
progression of CRC (Figure 3). Anticancer therapy tar-
geted to the stroma is a promising strategy for inhibiting
tumour progression.
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